Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. In the meantime, lobbyists working for the drug manufacturers successfully blocked efforts by Medicare administrators to stop paying for the higher (harmful) doses. Could the FDA and other U.S.
130 
Let's personalize your content